Comparative Pharmacology
Head-to-head clinical analysis: CALCIUM GLUCONATE IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIUM GLUCONATE IN SODIUM CHLORIDE versus MAGNESIUM SULFATE IN PLASTIC CONTAINER.
CALCIUM GLUCONATE IN SODIUM CHLORIDE vs MAGNESIUM SULFATE IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium gluconate provides calcium ions, which are essential for normal cardiac function, nerve transmission, and muscle contraction. In hyperkalemia, calcium antagonizes the cardiotoxic effects of potassium by stabilizing the cardiac cell membrane.
Magnesium sulfate causes decreased release of acetylcholine at the neuromuscular junction, reducing muscle contractility. It also blocks calcium channels, leading to vasodilation and anticonvulsant effects.
1-2 g calcium gluconate (9.3-18.6 mEq calcium) intravenously over 10-20 minutes, may repeat if needed. For continuous infusion: 0.5-2 mg/kg/hour calcium gluconate. Max rate: 1-2 mL/minute of 10% solution.
IV: 1-4 g as a 10-20% solution, rate not exceeding 1 g/min; for eclampsia: 4-5 g IV bolus then 1-2 g/hour IV infusion.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function; prolonged in renal impairment (up to 24-48 hours).
Normal renal function: 4–6 hours (terminal). In oliguria or anuria, half-life may extend to >24 hours, requiring dose adjustment.
Primarily renal; ~80% of administered calcium is excreted in urine via glomerular filtration with tubular reabsorption; fecal excretion accounts for ~15-20% as unabsorbed or secreted calcium; negligible biliary excretion.
Primarily renal (glomerular filtration); >90% excreted unchanged in urine. Biliary/fecal elimination is negligible (<1%).
Category A/B
Category C
Electrolyte
Electrolyte